Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Corp.

www.bostonscientific.com

Latest From Boston Scientific Corp.

German Court Rules For Boston Scientific In TAVR Patent Tiff

A German court has issued a preliminary ruling favoring Boston Scientific in its most recent intellectual property dispute with Edwards LifeSciences. The ruling would allow Boston Scientific to block Edwards’ Sapien 3 Ultra from the German market.

Medical Device Cardiology

A Chance To Own The Venous Space: BTG Acquires Novate

Complications with inferior vena cava (IVC) filters and subsequent patient-injury lawsuits have made this a tricky space for medical technology innovators, bu BTG has not been deterred. The UK company has entered the fray with a technology developed by Novate Medical, and as a bioconvertible product BTG believes it has key advantages compared with other offerings. 

Innovation Surgical Procedures

Market Intel: Martin Leon's TAVR Technology Tour Of The Future

Transcatheter aortic valve replacement pioneer Martin Leon discussed what is coming down the pike for technologies in the TAVR and heart valve device space at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. Here is a run-down of what he highlighted, including AI-driven technologies that promise to improve patient access and outcomes. This is the first of a two-part series focusing on innovations in interventional cardiology. 

Surgical Procedures Cardiovascular

Bringing The Clinician's Rationale Into The Heart Of Strategic Decision-Making At Boston Scientific

Boston Scientific Corp. has been back on the M&A trail in a big way in 2018, with a succession of strategic additions of various sizes that all have potential patient and shareholder impact across – and beyond – its established divisions. Chief medical officer of 18 months Ian Meredith explains the thought processes driving this policy, and the added dimension a CMO can bring to the overall question of strategy.

Leadership M & A
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register